Table IV. Summary of differentially excreted uromodulin peptides from the validation phase. Differential excretion was determined using the Mann-Whitney test (p < 0.05). Fold change represents the ratio of the median peptide excretion of youths with type 1 diabetes (T1D) to the median peptide excretion of healthy controls (HC). AHSG, alpha-2-HS-glycoprotein; ALB, albumin; APOA1, apolipoprotein A1; CLU, clusterin; FXYD2, Na+/K+-transporting ATPase subunit gamma; LTBP4, latent transforming growth factor beta binding protein 4; UQ, unable to quantify; UMOD, uromodulin.
| Peptide | Name | Fold change (T1D:HC) | P |
|---|---|---|---|
| SGSVIDQSRVLNLGPI | UMOD-1 | 2.91 | 0.0183 |
| SGSVIDQSRVLNLGPITR | UMOD-2 | 0.75 | 0.0672 |
| SVIDQSRVLNLGPI | UMOD-3 | 12.83 | 0.0002 |
| SVIDQSRVLNLGPIT | UMOD-4 | 4.16 | 0.0006 |
| SVIDQSRVLNLGPITR | UMOD-5 | 4.41 | 0.0004 |
| SVIDQSRVLNLGPITRK | UMOD-6 | UQ | — |
| VIDQSRVLNLGPI | UMOD-7 | 6.94 | 0.0024 |